4 / 5 phases complete
Read from what is actually in the database — runs, designs, filter verdicts, assay pages — not from the stage letter typed on the page.
A–C
Target prep
Done
PD-L1CD274 19-127PDB 4ZQK5 hotspots
The GFCC′ face of the IgV domain — the same front β-sheet PD-1 docks against, overlapping the atezolizumab/durvalumab epitope. Solvent-exposed, clear of the N-glycans, and clinically validated as a face whose blockade is functionally meaningful rather than just structurally occluding.